About lite strategy - MEIP
Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.
MEIP At a Glance
Lite Strategy, Inc.
9920 Pacific Heights Boulevard
San Diego, California 92121
| Phone | 1-858-369-7100 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -15,945,000.00 | |
| Sector | Health Technology | Employees | 4 | |
| Fiscal Year-end | 06 / 2026 | |||
| View SEC Filings |
MEIP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.972 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.091 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
MEIP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,986,250.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MEIP Liquidity
| Current Ratio | 13.504 |
| Quick Ratio | 13.504 |
| Cash Ratio | 13.302 |
MEIP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -53.453 |
| Return on Equity | -63.843 |
| Return on Total Capital | -94.176 |
| Return on Invested Capital | -63.843 |
MEIP Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |